FDA Issues Policy on Remote Ophthalmic Assessment and Monitoring Devices During Pandemic

Posted on

The U.S. Food and Drug Administration has issued a new guidance to help expand remote ophthalmic assessment and monitoring devices during the COVID-19 pandemic, according to a press release.

The AAO has previously recommended that ophthalmologists stop routine care and only treat urgent cases. Remote assessment will allow providers to care for patients while limiting potential exposure to the virus.

The policy will remain in effect until the public health emergency is over.

Read the full guidance here.

Related Articles
Does having wet AMD effect COVID-19 outcomes?
Jun 08, 2021
Daily wearers of eyeglasses may be less susceptible to COVID-19
Sep 17, 2020
Systemic clinical symptoms, cough linked with ocular symptoms in kids with COVID-19
Aug 30, 2020